These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3430773)

  • 21. [Characteristics of the pharmacokinetics of drugs in renal failure].
    Nadzhimutdinov KN; Krakovskiĭ ME
    Farmakol Toksikol; 1985; 48(5):109-13. PubMed ID: 3908139
    [No Abstract]   [Full Text] [Related]  

  • 22. HPLC-studies on nonmercapt-mercapt conversion of human serum albumin.
    Sogami M; Era S; Nagaoka S; Kuwata K; Kida K; Miura K; Inouye H; Suzuki E; Hayano S; Sawada S
    Int J Pept Protein Res; 1985 Apr; 25(4):398-402. PubMed ID: 4019023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxaprozin pharmacokinetics in patients with congestive heart failure.
    Ochs HR; Greenblatt DJ; Knüchel M
    Arzneimittelforschung; 1986 Dec; 36(12):1837-40. PubMed ID: 3566846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form.
    Niwa T; Aiuchi T; Nakaya K; Emoto Y; Miyazaki T; Maeda K
    Clin Nephrol; 1993 Feb; 39(2):92-6. PubMed ID: 8448924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of haemodialysis and continuous ambulatory peritoneal dialysis on the plasma clearance of an albumin-bound furan dicarboxylic acid.
    Costigan MG; Yaqoob M; Lindup WE
    Nephrol Dial Transplant; 1995; 10(5):648-52. PubMed ID: 7566577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiological disposition of fenoprofen in man. 3. Metabolism and protein binding of fenoprofen.
    Rubin A; Warrick P; Wolen RL; Chernish SM; Ridolfo AS; Gruber CM
    J Pharmacol Exp Ther; 1972 Nov; 183(2):449-57. PubMed ID: 5083556
    [No Abstract]   [Full Text] [Related]  

  • 27. Structural requirements for drug binding to site II on human serum albumin.
    Wanwimolruk S; Birkett DJ; Brooks PM
    Mol Pharmacol; 1983 Nov; 24(3):458-63. PubMed ID: 6195516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New approaches to the removal of protein-bound toxins from blood plasma of uremic patients.
    Sarnatskaya VV; Yushko LA; Sakhno LA; Nikolaev VG; Nikolaev AV; Grinenko DV; Mikhalovsky SV
    Artif Cells Blood Substit Immobil Biotechnol; 2007; 35(3):287-308. PubMed ID: 17573628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A major endogenous ligand substance involved in renal failure.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 49(4):277-80. PubMed ID: 3412543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacokinetics of alminoprofen in healthy subjects. Influence of the time of administration].
    Paillet M; Merdjan H; Doucet D
    Therapie; 1986; 41(6):413-6. PubMed ID: 3810535
    [No Abstract]   [Full Text] [Related]  

  • 31. Liquid chromatographic tandem mass spectrometric assay for the uremic toxin 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid in human plasma.
    Huang Y; Sun H; Frassetto L; Benet LZ; Lin ET
    Rapid Commun Mass Spectrom; 2006; 20(10):1611-4. PubMed ID: 16628600
    [No Abstract]   [Full Text] [Related]  

  • 32. Binding of diuretics to human serum albumin and to human serum from healthy adults and patients with renal failure.
    Nakano M; Fujii K; Goto S
    Chem Pharm Bull (Tokyo); 1979 Jan; 27(1):101-8. PubMed ID: 428019
    [No Abstract]   [Full Text] [Related]  

  • 33. Correlates affecting survival in chronic hemodialysis patients: the combined impact of albumin and high hemoglobin levels on improving outcomes, local and national results.
    Capelli JP; Kushner H
    Hemodial Int; 2008 Oct; 12(4):450-62. PubMed ID: 19090868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal function and serum albumin at the start of dialysis in 514 Chinese ESRD in-patients.
    Liu H; Peng Y; Liu F; Xiao H; Chen X; Huang A; Liu Y
    Ren Fail; 2008; 30(7):685-90. PubMed ID: 18704816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. II.
    Sogami M; Era S; Nagaoka S; Kuwata K; Kida K; Shigemi J; Miura K; Suzuki E; Muto Y; Tomita E
    J Chromatogr; 1985 Sep; 332():19-27. PubMed ID: 4055942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased drug binding by serum albumin during renal failure.
    Campion DS
    Toxicol Appl Pharmacol; 1973 Jul; 25(3):391-7. PubMed ID: 4580494
    [No Abstract]   [Full Text] [Related]  

  • 37. Isolation and characterization of an endogenous drug-binding inhibitor present in uremic serum.
    Mabuchi H; Nakahashi H
    Nephron; 1986; 44(4):277-81. PubMed ID: 3796769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of cyanate to the albumin binding defect of uremia.
    Bachmann K; Valentovic M; Shapiro R
    Biochem Pharmacol; 1981 May; 30(10):1059-63. PubMed ID: 7259792
    [No Abstract]   [Full Text] [Related]  

  • 39. A circular dichroic investigation of the binding of fenoprofen, 2(3-phenoxyphenyl)-propionic acid, to human serum albumin.
    Perrin JH
    J Pharm Pharmacol; 1973 Mar; 25(3):208-12. PubMed ID: 4146320
    [No Abstract]   [Full Text] [Related]  

  • 40. Species difference in the competitive binding of 2-(4'-hydroxybenzeneazo)benzoic acid (HBABA) and alpha-(4-chlorophenoxy)-alpha-methylpropionic acid (CPMPA) to serum albumin. A possible model system for studying allosteric transitions.
    Witiak DT; Sokoloski TD; Whitehouse MW; Hermann F
    J Med Chem; 1969 Sep; 12(5):754-61. PubMed ID: 5812181
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.